L. Daniel Browne
2016
In 2016, L. Daniel Browne earned a total compensation of $2.9M as President and Chief Executive Officer at Revance Therapeutics, a 23% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $273,488 |
|---|---|
| Option Awards | $1,689,835 |
| Salary | $510,000 |
| Stock Awards | $428,000 |
| Total | $2,901,323 |
Browne received $1.7M in option awards, accounting for 58% of the total pay in 2016.
Browne also received $273.5K in non-equity incentive plan, $510K in salary and $428K in stock awards.
Rankings
In 2016, L. Daniel Browne's compensation ranked 3,320th out of 14,075 executives tracked by ExecPay. In other words, Browne earned more than 76.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,320 out of 14,075 | 76th |
Division Manufacturing | 1,154 out of 5,489 | 79th |
Major group Chemicals And Allied Products | 347 out of 1,895 | 82nd |
Industry group Drugs | 250 out of 1,538 | 84th |
Industry Pharmaceutical Preparations | 195 out of 1,176 | 83rd |
Source: SEC filing on March 24, 2017.
Browne's colleagues
We found two more compensation records of executives who worked with L. Daniel Browne at Revance Therapeutics in 2016.